导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.43% | 2291/4762 |
| 近一周 | -1.34% | 2040/5451 |
| 近一月 | -7.03% | 4403/5408 |
| 近一季 | 15.78% | 91/5218 |
| 近半年 | 4.72% | 848/4907 |
| 近一年 | -14.57% | 3661/4387 |
| 近两年 | 24.72% | 2518/2950 |
| 近三年 | -6.90% | 1999/2249 |
| 成立以来 | -3.30% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.82% 3429/4961 |
-0.38% 3293/5312 |
- - |
- - |
| 2025 | 9.28% 2872/4813 |
3.73% 1047/3635 |
2.17% 1794/4076 |
22.13% 1689/4524 |
-15.58% 4367/4813 |
| 2024 | -19.04% 2526/3463 |
-14.32% 2520/2808 |
-11.18% 2513/3014 |
17.25% 1225/3129 |
-9.26% 2913/3463 |
| 2023 | -5.07% 713/2656 |
-0.21% 1784/2280 |
-7.72% 1896/2385 |
0.85% 336/2515 |
2.22% 69/2655 |
| 2022 | -22.53% 1072/2207 |
-11.70% 540/1919 |
-3.49% 1823/2016 |
-16.78% 1497/2113 |
9.24% 232/2208 |
| 2021 | -14.96% 1152/1822 |
-4.48% 865/1255 |
8.96% 595/1330 |
-12.18% 1294/1466 |
-6.96% 1558/1822 |
| 2020 | 54.18% 144/1250 |
13.35% 9/1028 |
35.77% 18/1067 |
4.01% 961/1164 |
-3.68% 1132/1184 |
| 2019 | - - |
- - |
- - |
12.84% 29/850 |
4.90% 768/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 国泰中证生物医药ETF联接A VS. 长安沪深300非周期A(740101) |